Dry and Wet Age-Related Macular Degeneration – Geographic Focus: China – Dry and Wet Age-Related Macular Degeneration – China In-Depth (China)

Age-related macular degeneration (AMD), which includes dry and wet AMD, is a leading cause of irreparable vision loss globally. In China, patients with wet AMD are typically treated with VEGF inhibitors (e.g., Lang Mu [conbercept], Lucentis [ranibizumab], Avastin [bevacizumab], Eylea [aflibercept]). These branded drugs will face competition from the multiple biosimilars of ranibizumab and aflibercept, which are set to enter the Chinese market during the forecast period. Moreover, several potentially more attractive drugs are in development, including Roche’s Vabysmo (faricimab), Novartis’s Beovu (brolucizumab), Regeneron’s high-dose aflibercept, and RemeGen’s RC-28E. Some of these agents may offer a dosing advantage over current agents. In contrast to the treatment of wet AMD, the treatment of dry AMD is limited because no prescription therapies are approved or are in the pipeline for this large subpopulation.

Questions answered

Content highlights

Geographies: China.

Primary research: Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys of 50 ophthalmologists

Epidemiology: Total, diagnosed, and drug-treated prevalent cases of dry and wet AMD in urban and rural China.

Forecast: 10-year, annualized, drug-level sales and patient share of key wet AMD therapies through 2032, based on primary and secondary market research to formulate bottom-up assumptions

Emerging therapies for wet AMD: Phase 3/PR: 5+ drugs; Phase 1/2: 10+ drugs.

Product description

China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific access and reimbursement environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.